# Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults

> **NCT05212818** · PHASE2 · TERMINATED · sponsor: **Techfields Inc** · enrollment: 19 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** TF0023

## Key facts

- **NCT ID:** NCT05212818
- **Lead sponsor:** Techfields Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-10
- **Primary completion:** 2023-02-03
- **Final completion:** 2023-03-08
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Low patient accrual.
- **Last updated:** 2024-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05212818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05212818, "Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05212818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*